
Regeneron Says Antibodies Show Success in Preventing COVID-19 Infections
Published on November 8, 2021
Regeneron said its monoclonal antibody treatment reduced the risk of contracting the disease by 81.6 percent among uninfected persons.

Regeneron said its monoclonal antibody treatment reduced the risk of contracting the disease by 81.6 percent among uninfected persons.